BioCentury
ARTICLE | Company News

Allergan, Serenity deal

April 5, 2010 7:00 AM UTC

Serenity granted Allergan exclusive, worldwide rights to develop and commercialize Ser-120 for all indications except primary nocturnal enuresis (pediatric bedwetting). Ser-120, which uses CPE-215 in...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article